Kenko Imalytics is a health-tech company delivering clinical, AI Software as a Medical Device (SaMD) for MRI decision support in oncology. We transform MRI-derived data into explainable, physiologically grounded imaging biomarkers that clinicians can interpret, trust, and act upon, turning clinical complexity into clinical trust.
As MRI examinations become more complex and workloads continue to rise, radiologists need quantitative, interpretable evidence that reduces uncertainty and strengthens decision-making. Kenko Imalytics brings that clarity through MRI-derived, explainable imaging biomarkers that turn complex multiparametric MRI into clinically interpretable insight for radiologists and multidisciplinary teams, including tumour boards.
At the core of Kenko Imalytics are explainable imaging biomarkers with clear physiological meaning that clinicians can interpret, discuss, and defend. By transforming MRI complexity into transparent, physiologically grounded insights, Kenko Imalytics supports a deeper understanding of tumour behaviour and brings confidence to every oncology decision.
Kenko Imalytics is built to support radiologists within real clinical workflows. It transforms complex multiparametric MRI into clear, quantitative insight that reduces uncertainty, strengthens clinical judgement, and supports more consistent interpretation. The role of the platform is to support, empower, and optimise, while preserving full clinician control and responsibility.
All Kenko Imalytics devices are built on a shared technological foundation for MRI data processing, quantitative biomarker extraction, and integration into hospital imaging workflows, while remaining independent products with their own clinical scope and regulatory pathway. This common platform powers a growing family of organ-specific Software as a Medical Device solutions across the Kenko portfolio.
Kenko Imalytics brings clinical confidence to cancer care through MRI-derived, explainable imaging biomarkers. By supporting radiologists and multidisciplinary teams with physiologically grounded, interpretable evidence, it enables faster, more confident and more defensible decisions across the cancer diagnostics pathway.
Your login details have been sent to the email address linked to your authorised account. Please
follow the instructions included in that email to
access the platform securely.
Thank you.